A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key ...
Genomic testing based on chromosome microarray (CMA) and Next Generation Sequencing (NGS) revolutionized clinical genetics. That said, microarray, targeted panel, exome and generic whole genome ...
Utilizing FIB-SEM, nanofluidic lab-on-a-chip devices for the analysis of single DNA molecules were characterized and fabricated. Direct FIB nanopatterning of silicon master stamps enables the quick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback